This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (C-CRISP)

This study has been completed.
Information provided by (Responsible Party):
Sanofi Identifier:
First received: December 23, 2010
Last updated: July 15, 2014
Last verified: July 2014

Primary Objective:

  • Response rate (by contrast CT scan)

Secondary Objectives:

  • Progression-free survival (PFS)
  • Overall survival (OS)

Condition Intervention Phase
Lung Neoplasms Drug: DOCETAXEL Radiation: Intensity Modulated Radiotherapy (IMRT) Drug: CISPLATIN Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Concurrent Chemoradiotherapy Using IMRT (With Single Photon Emission Computed Tomography/SPECT-CT to Define Functional Lung Volume and Positron Emission Tomography/PET to Define Gross Tumour Volume/GTV) and Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer (NSCLC)

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Response rate (by contrast CT scan) [ Time Frame: 12 weeks after completion of adjuvant chemotherapy or within 4 weeks after premature study discontinuation ]

Secondary Outcome Measures:
  • Progression Free survival (PFS) [ Time Frame: Day 1 of treatment to the date of objective disease progression ]
  • Overall survival (OS) [ Time Frame: Day 1 of treatment to the date of death due to any cause ]
  • Adverse events (including oesophageal and pulmonary toxicities) [ Time Frame: Informed consent signature up to 12 weeks after completion of treatment ]

Enrollment: 34
Study Start Date: January 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: IMRT & docetaxel-cisplatin

Concurrent chemo-RT:

Radiotherapy: IMRT - Docetaxel 20mg/m2 + cisplatin 20mg/m2 weekly for 6 weeks -

Resting period: 2 weeks -

Adjuvant chemotherapy: Q3W for 2 cycles Docetaxel 35 mg/m² IV infusion for 1 hour on D1&8 - Cisplatin 35 mg/m² on D1&8 -

Dexamethasone for a total of 3 doses is to be given at a dose of 4 mg at 12 hours, 1 hour before and 12 hours after docetaxel administration

Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
Radiation: Intensity Modulated Radiotherapy (IMRT)
2 Gy per fraction
Pharmaceutical form: solution for infusion Route of administration: intravenous

Detailed Description:
The duration of the study for each patient will include an up to 6-week screening phase, 12 weeks treatment phase (including a resting period of 2 weeks) followed by a long-term follow-up.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Pathologically proven locally advanced, inoperable, confirmed by PET scan (thorax/ upper abdomen) to be International stage III (2009) NSCLC and without multifocal tumours in the lung
  • Disease volume encompassible within a tolerable Planning Target Volume treated to 66 Gy
  • FEV1 (Force Expiratory Volume in 1 Second) >1000 ml
  • Hemoglobin ≥ 9.0 g/dl
  • Absolute neutrophil count (ANC) ≥ 1,500/mm3
  • Platelet count ≥ 100,000/mm3
  • Total bilirubin ≥ 1.5 times the upper limit of normal
  • ALT (Alanine Aminotransferase) and AST (Aspartate transaminase) ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for patients with liver derangement)
  • ECOG (Eastern Cooperative Oncology Group) PS 0-1

Exclusion criteria:

  • Previous treatment with chest radiotherapy, chemotherapy or molecularly targeted agents
  • Inadequate lung function (Exercise tolerance less than 1 FOS/Fight of stairs, FEV1 < 1 L/sec, or raised pCO2)
  • History of hypersensitivity or contraindication to the study drugs or pre-medications or products formulated in polysorbate 80
  • Pregnant or breast-feeding women, or women with child-bearing potential who are not following an effective method of contraception and/or who are unwilling or unable to be tested for pregnancy (either by serum or urine pregnancy test before study entry
  • Participation in a clinical trial with any investigational drug used and within 30 days prior to study entry

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01266512

Hong Kong
Sanofi-Aventis Administrative Office
Hong Kong, Hong Kong
Sponsors and Collaborators
Study Director: Clinical Sciences & Operations Sanofi
  More Information

Responsible Party: Sanofi Identifier: NCT01266512     History of Changes
Other Study ID Numbers: DOCET_L_05158
U1111-1115-3573 ( Other Identifier: UTN )
Study First Received: December 23, 2010
Last Updated: July 15, 2014

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on July 26, 2017